ELDN   $4.07  5.71% Market Closed After Close 4.18 2.70%

Eledon Pharmaceuticals Inc
Last Events:

2023-08-09 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-09 Trend Power changed from medium strength to strong.

2023-08-06 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: exit from the oversold zone.

2023-08-06 Trend Power changed from strong to medium strength.

2023-08-05 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-05 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-04 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: main and signal line crossing.

2023-08-04 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 5
Target Price Mean 12.50
Mean unverified/preliminary 12.50 / 12.50
Target Price Low / High 7.00 / 20.50
Median / STD DEV 10.00 / 5.59
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy None
macd None None None
stoch ActivelyBuy None None
ma20 ActivelyBuy ActivelyBuy ActivelyBuy
ma50 ActivelyBuy None None
ma100 ActivelyBuy ActivelyBuy ActivelyBuy
Candlestick PatternNov. 19, 2024 Deliberation Block Formation - consists of three black bodies with consecutively lower closes in a downtrend. The final day is a short black candlestick, a spinning top or a doji. Considered to be a bullish reversal pattern.
ISIN US28617K1016
ceo Dr. David-Alexandre C. Gros M.D., Ph.D.
Website https://eledon.com
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.